Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 781

1.

Molecular modulation of estrogen-induced apoptosis by synthetic progestins in hormone replacement therapy: an insight into the women's health initiative study.

Sweeney EE, Fan P, Jordan VC.

Cancer Res. 2014 Dec 1;74(23):7060-8. doi: 10.1158/0008-5472.CAN-14-1784. Epub 2014 Oct 10.

PMID:
25304262
2.

Hormone therapy and venous thromboembolism among postmenopausal women.

Scarabin PY.

Front Horm Res. 2014;43:21-32. doi: 10.1159/000360554. Epub 2014 Jun 10. Review.

PMID:
24943295
3.

Hormone therapy and hemostasis among postmenopausal women: a review.

Canonico M.

Menopause. 2014 Jul;21(7):753-62. doi: 10.1097/GME.0000000000000296. Review.

PMID:
24937030
4.

Combined estrogen replacement therapy on metabolic control in postmenopausal women with diabetes mellitus.

Xu Y, Lin J, Wang S, Xiong J, Zhu Q.

Kaohsiung J Med Sci. 2014 Jul;30(7):350-61. doi: 10.1016/j.kjms.2014.03.002. Epub 2014 Apr 18. Review.

PMID:
24924841
6.

Effects of hormone replacement therapy on cerebral serotonin-1A receptor binding in postmenopausal women examined with [carbonyl-¹¹C]WAY-100635.

Kranz GS, Rami-Mark C, Kaufmann U, Baldinger P, Hahn A, Höflich A, Savli M, Stein P, Wadsak W, Mitterhauser M, Winkler D, Lanzenberger R, Kasper S.

Psychoneuroendocrinology. 2014 Jul;45:1-10. doi: 10.1016/j.psyneuen.2014.03.004. Epub 2014 Mar 20.

PMID:
24845171
7.

Is breast cancer risk the same for all progestogens?

Stute P.

Arch Gynecol Obstet. 2014 Aug;290(2):207-9. doi: 10.1007/s00404-014-3270-0.

PMID:
24838289
8.

Insulin resistance and medial prefrontal gyrus metabolism in women receiving hormone therapy.

Rasgon NL, Kenna HA, Wroolie TE, Williams KE, DeMuth BN, Silverman DH.

Psychiatry Res. 2014 Jul 30;223(1):28-36. doi: 10.1016/j.pscychresns.2014.04.004. Epub 2014 Apr 15.

PMID:
24819305
9.

Systemic delivery of estradiol, but not testosterone or progesterone, alters very low density lipoprotein-triglyceride kinetics in postmenopausal women.

Smith GI, Reeds DN, Okunade AL, Patterson BW, Mittendorfer B.

J Clin Endocrinol Metab. 2014 Jul;99(7):E1306-10. doi: 10.1210/jc.2013-4470. Epub 2014 Apr 2.

PMID:
24694337
10.

Nanostructured transdermal hormone replacement therapy for relieving menopausal symptoms: a confocal Raman spectroscopy study.

Botelho MA, Queiroz DB, Barros G, Guerreiro S, Fechine P, Umbelino S, Lyra A, Borges B, Freitas A, Queiroz DC, Ruela R, Almeida JG, Quintans L Jr.

Clinics (Sao Paulo). 2014 Feb;69(2):75-82. doi: 10.6061/clinics/2014(02)01.

11.

Current and evolving approaches to individualizing estrogen receptor-based therapy for menopausal women.

Santen RJ, Kagan R, Altomare CJ, Komm B, Mirkin S, Taylor HS.

J Clin Endocrinol Metab. 2014 Mar;99(3):733-47. doi: 10.1210/jc.2013-3680. Epub 2014 Jan 1. Review.

PMID:
24423357
12.

Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status.

Munsell MF, Sprague BL, Berry DA, Chisholm G, Trentham-Dietz A.

Epidemiol Rev. 2014;36:114-36. doi: 10.1093/epirev/mxt010. Review.

13.

Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France.

Cordina-Duverger E, Truong T, Anger A, Sanchez M, Arveux P, Kerbrat P, Guénel P.

PLoS One. 2013 Nov 1;8(11):e78016. doi: 10.1371/journal.pone.0078016. eCollection 2013.

14.

Hormone therapy in postmenopausal women and risk of endometrial hyperplasia: a Cochrane review summary.

Roberts H, Hickey M, Lethaby A.

Maturitas. 2014 Jan;77(1):4-6. doi: 10.1016/j.maturitas.2013.10.002. Epub 2013 Oct 11. No abstract available.

PMID:
24182544
15.

The Women's Health Initiative trial and related studies: 10 years later: a clinician's view.

Gurney EP, Nachtigall MJ, Nachtigall LE, Naftolin F.

J Steroid Biochem Mol Biol. 2014 Jul;142:4-11. doi: 10.1016/j.jsbmb.2013.10.009. Epub 2013 Oct 27. Review.

PMID:
24172877
16.

Sex hormone levels and risk of breast cancer with estrogen plus progestin.

Farhat GN, Parimi N, Chlebowski RT, Manson JE, Anderson G, Huang AJ, Vittinghoff E, Lee JS, Lacroix AZ, Cauley JA, Jackson R, Grady D, Lane DS, Phillips L, Simon MS, Cummings SR.

J Natl Cancer Inst. 2013 Oct 2;105(19):1496-503. doi: 10.1093/jnci/djt243. Epub 2013 Sep 16.

17.

Progestin effects on cell proliferation pathways in the postmenopausal mammary gland.

Wood CE, Branstetter D, Jacob AP, Cline JM, Register TC, Rohrbach K, Huang LY, Borgerink H, Dougall WC.

Breast Cancer Res. 2013;15(4):R62.

19.

Impact of hormone therapy on quality of life after menopause.

Utian WH, Woods NF.

Menopause. 2013 Oct;20(10):1098-105. doi: 10.1097/GME.0b013e318298debe. Review.

PMID:
23799357
20.

Association of oxidative stress and memory performance in postmenopausal women receiving estrogen-progestin therapy.

Shafin N, Zakaria R, Hussain NH, Othman Z.

Menopause. 2013 Jun;20(6):661-6. doi: 10.1097/GME.0b013e31827758c6.

PMID:
23715378
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk